Pancreatic cancer — frontier options in North Carolina

12 open options

TRIALPHASE1 / PHASE2RECRUITING
Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel
Gemcitabine · Nab paclitaxel · Erlotinib — 1 site
TRIALPHASE1RECRUITING
Autologous CAR-T Cells Targeting B7-H3 in PDAC
iC9-CAR.B7-H3 T cell infusion — 1 site
EXPANDED ACCESSAVAILABLE
Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
daraxonrasib — 257 sites
TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 220 sites
TRIALPHASE2RECRUITING
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic Cancer
VS-7375 · cetuximab — 28 sites
TRIALPHASE2RECRUITING
Tumor Subtypes in Subjects on FOLFIRINOX With Non-Metastatic Pancreatic Cancer
Oxaliplatin · Leucovorin · Irinotecan Hydrochloride — 1 site
TRIALPHASE3RECRUITING
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Biopsy Procedure · Biospecimen Collection · Capecitabine — 333 sites
TRIALPHASE2RECRUITING
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
APL-101 Oral Capsules — 35 sites
TRIALPHASE1RECRUITING
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
MRTX1719 — 25 sites
TRIALPHASE2RECRUITING
Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma
Stereotactic body radiotherapy (SBRT) · Zimberelimab · Quemliclustat — 5 sites
TRIALPHASE1 / PHASE2RECRUITING
Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients
TNG462 · RMC-9805 · RMC-6236 — 18 sites
TRIALPHASE2 / PHASE3RECRUITING
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Zanzalintinib · Everolimus — 120 sites

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.